Compare GABC & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | BLFS |
|---|---|---|
| Founded | 1910 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 1989 |
| Metric | GABC | BLFS |
|---|---|---|
| Price | $39.40 | $25.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.50 | $31.50 |
| AVG Volume (30 Days) | 86.9K | ★ 394.0K |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $312,775,000.00 | $100,144,000.00 |
| Revenue This Year | $47.67 | $25.65 |
| Revenue Next Year | $6.23 | $14.81 |
| P/E Ratio | $13.80 | ★ N/A |
| Revenue Growth | 26.55 | ★ 87.53 |
| 52 Week Low | $32.75 | $19.10 |
| 52 Week High | $46.23 | $29.62 |
| Indicator | GABC | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 45.58 |
| Support Level | $37.73 | $23.57 |
| Resistance Level | $40.37 | $27.24 |
| Average True Range (ATR) | 0.81 | 1.00 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 65.34 | 51.77 |
German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.